Abstract

Reducing effectively toxic side effects is a challenging subject in drug development. The reported herein cocrystallization of pyrazinamide with quercetin has complementary advantages, enhancing the in vitro/vivo performance of quercetin and taming the pharmacokinetic synergy of quercetin and pyrazinamide, almost removing pyrazinamide induced hepatotoxicity. The findings stimulate the application of active pharmaceutical ingredient–nutraceutical cocrystallization to solve the toxicity issue of drugs.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call